Short-Term Recall and Reprocess Therapy for Post Traumatic Stress Disorder (PTSD)

Inclusion Criteria:

• • Diagnosis of PTSD with a score of 25 or higher (i.e. severe PTSD) on theClinician- Administered PTSD Scale (CAPS-5) at screening.

• Subjects on FDA-approved antidepressants, trazodone, atypical neuroleptic,prazosin, or clonidine may enter the study if they have been on a stabletreatment, as determined by the study clinician, for at least 4 weeks prior torandomization. Following randomization, small changes to doses may be allowableat the PI's discretion.

• Able to provide written informed consent.

• Able to read and write English/Hebrew.

Exclusion Criteria:

• • Patients with a diagnostic history of bipolar disorder, borderline personalitydisorder, obsessive-compulsive disorder, schizophrenia or schizoaffective disorderor currently exhibiting psychotic features as determined by the clinical interview;dementia or suspicion thereof, are excluded. Other DSM Axis I disorders arepermitted as long as they are not considered primary disorders.

• Patients with a history of antidepressant-induced hypomania or mania asdetermined by open-ended psychiatric interview.

• Current, ongoing serious suicidal risk as assessed by evaluating.

• Moderate severity or greater Substance Use Disorder (excepting Alcohol UseDisorder) during the 3 months prior to randomization, as determined by theSCID.

• History of traumatic brain injury (TBI) with loss of consciousness for morethan 24 hours or posttraumatic amnesia for more than 7 days may be consideredif the trauma occurred more than 1 year ago, and no more than minimal symptomshave persisted over the past year.

• Any significant history of neurological illness or heart disease.

• Any signs of major medical or neurological illness on examination or as aresult of ECG screening or laboratory studies.

• Any history indicating learning disability or mental retardation.